anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Our study focuses on patients over 18 years, with unilateral or bilateral parotid or submandibular salivary symptoms. Each patient included is given a MRI sialography and a 3D-CBCT sialography at a later stage when the acute episode has subsided. Images are archived on the Carestream Picture Archiving Communication System (PACS). Interpretation is achieved after Multi-Planar Reconstruction (MPR), Maximal Intensity Projection (MIP) and three-dimensional rendering. A primary radiological analysis of the two procedures is systematically done by a specialist radiologist for the diagnostic and therapeutic care of the patient. A second radiological data analysis is carried out at the end of the study, by a specialized radiologist, different from the first one, to asses the two radiological examinations.

The primary outcome measure is the capability of the radiological technique to detect a ductal salivary feature. Secondary outcomes include the clinical characteristics of the patients, the diagnostic capabilities in identifying the salivary lesions, their number, their precise location and measurements. A primary side effect in catheterization and dosimetric parameters for the CBCT technique will be systematically recorded.
A method includes receiving stress-related measurements collected by one or more stress sensors, where the stress-related measurements represent one or more physiological responses of a user to a stressor. The method also includes receiving context data collected by one or more context sensors, where the context data represents a context associated with the user. The method further includes determining stress profile features associated with the user based on the stress-related measurements. The method also includes providing the stress profile features to a trained stress profile identification machine learning model to select a stress profile from among multiple candidate stress profiles for association with the user. The method further includes providing the selected stress profile and the context data to a trained stress intervention recommendation machine learning model to select a stress intervention activity for the user. In addition, the method includes recommending the selected stress intervention activity to the user.
PURPOSE:To obtain a hydrophilic porous body sterilizable with gamma-rays by holding a polymer having hydrophilic property and gamma-ray resistance on the surface of a continuous layer of a synthetic polymer forming a porous base material. CONSTITUTION:A polymer having hydrophilic property and gamma-ray resistance, e.g. polyalkoxyalkyl (meth)acrylate is held on the surface of a continuous layer of a synthetic polymer, e.g. polyolefin or halogenated polyolefin forming a porous base material by >=5wt.% of the amt. of the base material to obtain a hydrophilic porous body having 0.02-20mum average pore diameter, 10-90% porosity and 10mum-5.0mm thickness. This porous body is sterilized with gamma-rays and is used in the field of medical treatment to purify blood and to separate plasma.
1514216 Microbiocidal compositions NELSON RESEARCH & DEVELOPMENT CO 8 July 1975 [18 July 1974] 28646/75 Heading A5B Microbiocidal compositions useful as a topical antiseptic spray, deodorant and/or antiperspirant contain no free water and comprise a water-soluble ene-diol compound, a water soluble catalytic metal compound of copper, iron, cobalt, nickel, manganese or titanium preferably cupric chloride and a propellant such as a halocarbon, with at least one of the ene-diol compound and the catalytic metal compound not in solution. The ene-diol compound may be squaric acid, ascorbyl palmitate, reductic acid, dihydroxyfumaric acid, dihydroxymaleic acid sodium ascorbate or ascorbic acid. The compositions may also include a nitrogen-containing inhibitor for stabilizing the ene-diol compound e.g. ammonium chloride; an emollient e.g. isopropyl myrisate; an astringent e.g. aluminium chloride or aluminium chlorhydrate; an anaesthetic e.g. benzocaine, butacaine, butylaminobenzoate and engenol; a fine powder e.g. talc or non-wettable starch; zinc oxide, zinc undecylenate, and/or undecylenic acid. Preferably the ene-diol compound is in the form of a powder and the copper compound is solubilized in ethanol.
Similar to the protocol previously outlined for the other two independent variables, the massage treatment (MT) will progress from anterior, to medial, to lateral and posterior shank, thigh, and hip. The treatment on each muscle tissue will follow the similar protocol as the Astym treatment (AT) group. However, the flat, non-treatment edge of the Evaluator®, Localizer®, and Isolator® will be put in contact with the muscle tissues in a direction parallel to the muscle fibers being treated, but without over pressure.7 The traditional treatment edge of the instrument has a tapered, machine edge and creates shear forces when glided across the tissue at an angle between 60 and 80 degrees.
Patients undergo leukapheresis on 35 to 21 days before Infusion Day (I-Day -35 to I-Day -21) and receive cyclophosphamide IV over 60 minutes and fludarabine IV over 30 minutes on I-Days -5, -4, and -3. Patients then receive CART-BCMA/CS1 IV on I-Day-0 on study. Patients undergo ECHO, ECG and MRI during screening. Patients undergo bone marrow biopsy and/or bone marrow aspirate screening, between I-Day -28 to I-Day -5, I-Day 30, and at 1 year post CART-BCMA/CS1 infusion. Patients also undergo FDG PET/CT during screening, between I-Day -28 to I-Day -5, I-Day 90 and I-Day 180 and every 3 months thereafter.
BACKGROUND AND AIMS: Carvedilol has emerged as the preferred β-blocker for treating portal hypertension. However, there is still a debate in dosing regimen, with a potential lower bioavailability in once-daily regimens. The aim of this study is to assess the acute effects of carvedilol posology in patients with clinically significant portal hypertension (CSPH), as a surrogate marker of bioavailability.
METHODS: In this experimental study, 34 patients with CSPH receiving carvedilol twice daily were asked to suppress the night dose of carvedilol, creating a standardized 24-hour dose interval. Spleen stiffness measurement (SSM) and liver stiffness measurement (LSM) by transient elastography (TE) were performed, with the exact interval between the last carvedilol administration and TE measurements consistently maintained at 24 hours and compared with values prior and under treatment.
RESULTS: Thirty-four patients were included, predominantly male (82.9%). SSM after suspending carvedilol for 24 hours [mean, 73.9kPa (SD, 17.0)] was significantly higher ( P < 0.001) than under treatment [mean, 56.3kPa (SD, 13.2)] and was not significantly different ( P = 0.908) from SSM prior to introduction of carvedilol [mean, 74.5kPa (SD, 12.4)]. Differences were also found in stratified analysis for carvedilol dosage, D'Amico classification stages, MELDNa scores, MELD3.0 scores, Child-Pugh class A and CSPH due to alcoholic cirrhosis. LSM after suspension was not significantly different from both under treatment and prior to treatment.
CONCLUSION: The differences in SSM after skipping one dose of carvedilol show both the importance of strict adherence to the prescribed dosing regimen to achieve the expected therapeutic benefits and the impact of twice daily prescription in bioavailability throughout the day.
Background: While studies have identified the negative cardiovascular effects of obesity, the effects of obesity on youth athletes are less studied. This study investigates the associations between obesity in youth athletes and exercise activity and exertional cardiac symptoms. Methods: The HeartBytes National Youth Database produced by Simon's Heart, a nonprofit that organizes adolescents' sports pre-participation examinations (PPEs), was used. This database contains demographic data, exercise-related symptoms, and electrocardiogram data obtained during PPEs. BMI was converted to percentiles, with obesity defined as BMI ≥95th percentile. Outcomes were evaluated using a chi-squared test with odds ratios (ORs) and 95% confidence intervals (CIs). Results: Of 7363 patients, there were 634 individuals with obesity. Youth athletes within normal weight ranges (5th-85th percentile) had higher exercise rates than those with underweight, overweight, or obesity (p < 0.001 for each). Athletes with obesity had higher odds of exertional symptoms overall (OR: 1.63 [CI: 1.36-1.96]; p < 0.001). However, for athletes who exercised >10 hours a week, there was no association between obesity and exertional symptoms. Athletes with obesity had higher odds of elevated blood pressure (OR: 5.35 [CI: 2.00-14.30]; p < 0.001) and hypercholesterolemia (OR: 3.84 [CI: 2.51-5.86]; p < 0.001). Conclusions: In this dataset, obesity in youth athletes is associated with decreased physical activity and increased exertional symptoms in general. Obesity is not associated with exertional symptoms in athletes who participated in higher weekly physical activity. Further studies are needed to elucidate the cause-effect relationship of these findings.
Volunteers will be instructed to use the whitening gel once a day for 2 hours, completing a total of 3 weeks of whitening procedure. Depending on the randomization, the bleaching procedure will be performed every other day or daily. In the upper arch, the teeth to be whitened will be from 15 to 25. The evaluations of efficacy, dental sensitivity and satisfaction will be carried out in the upper and lower arch. The color will be recorded before, weekly for 1 month, 6 months and 12 months after finishing the treatment. Shade assessment using the subjective method will be recorded with the Vita Classical color scale (Vita Zahnfabrik, Bad Säckingen, Germany), it will also be determined with the Vita 3D-MASTER scale (Vita Zahnfabrik, Bad Säckingen, Germany). For objective evaluation, the Vita Easyshade spectrophotometer (Vita Zahnfabrik, Bad Säckingen, Germany) will be used, according to the CIEL\*a\*b\* system.
The invention relates to a method for purifying recombined hansenula polymorpha hepatitis E virus-like particles and application. The method comprises the following steps: cultivating and fermenting working seed lot recombined hepatitis E vaccine engineering strains, and collecting a fermented culture; sequentially performing cell disruption, clarification, ultra-filtration, silica gel adsorption, ultra-filtration and concentration liquid change, chromatographic purification, desalination, disinfection and filtration on the culture to obtain the purified recombined hansenula polymorpha hepatitis E virus-like particles. The size of the purified recombined hansenula polymorpha hepatitis E virus-like particles is in accordance with the theoretical size of natural hepatitis E virus particles and is 27-34nm, a gene sequence is in accordance with a theoretical gene sequence, the expressed foreign protein molecular weight is in accordance with the expected target protein size, and the recombined hansenula polymorpha hepatitis E virus-like particles are good in immunogenicity. The invention also discloses the application of the recombined hansenula polymorpha hepatitis E virus-like particles in preparation of vaccine. The recombined hansenula polymorpha hepatitis E virus-like particles are mixed with an aluminum adjuvant to form the vaccine. An animal immunogenicity detection result shows that the vaccine prepared from the recombined hansenula polymorpha hepatitis E virus-like particles is good in immunogenicity.
A composition for improving antiwrinkle or skin whitening is provided to increase the improvement of antiwrinkle and skin whitening by using a mixture of vitamin C and E, pine tree extract and coenzyme Q10. A composition for improving anti-wrinkling or skin whitening comprises an mixture of vitamin C and E, pine tree extract and coenzyme Q10 as an active ingredient. The weight ratio of vitamin C, E, pine tree extract and coenzyme Q10 is 30-75:4-35:1-30:5-30. The content of the mixture is 0.2-100 weight% based on the total weight. The composition further comprises one or more selected from gamma-linolenic acid, grape seed extract, rose hip extract, and germinated brown rice extracts. The composition is used as one selected from food, skin external preparation, cosmetic material, washing agent.
NEW MATERIAL:A specific antigen protein of hepatitis of non-A non-B type containing an amino sequence shown by the formula or part thereof and a DNA fragment coding the protein. USE:An antigen protein is effective for detecting an antibody against hepatitis of non-A non-B type and a DNA fragment is useful as a probe for detecting a gene of specific antigen related to hepatitis of non-A non-B type by nucleic acid hybridization and a reagent for genetic diagnosis such as primer of genetic amplification. PREPARATION:RNA of hepatitis virus of non-A non-B type is extracted from plasma, serum or liver tissue of patient of hepatitis of non-A non-B type. cDNA is obtained from the prepared RNA fraction by random primer method, inserted into bacteriophage lambda gt11 and Escherichia coli Y1,090 strain, etc., is infected with the bacteriophage. Plaque produced by culture is transferred to a nitrocellulose membrane and treated with serum retaining specific antibody of hepatitis of non-A non-B type to detect an antibody reaction positive clone. Escherichia coli is infected with the clone, amplified and the objective DNA fragment is isolated. The DNA fragment is manifested to give an antigen protein.
Pelvic floor manual therapy is a clinical approach utilizing specifics hands-on mobilizing techniques to treat soft tissues. The technique require mobilization of soft-tissue by myofascial stretching maneuvers intended to improve bio-mechanical elasticity. The therapeutic protocol will be applied for 4 weeks.
PROBLEM TO BE SOLVED: To solve such problems in conventional methods that great time and cost are required for sorting out for dead leaves and dead parts of leaves when harvesting or after harvesting Sasa veitchii (Carr.) Rehd. and that all of the harvested Sasa veitchii (Carr.) Rehd. cannot be used as a raw material, because of conventionally using only green leaves without containing dead leaves as a raw material of Sasa veitchii (Carr.) Rehd., as well as a subject that the Sasa veitchii (Carr.) Rehd. extract extracted from green leaves as a raw material has a disagreeable smell unique to Sasa.SOLUTION: Sasa veitchii (Carr.) Rehd. extract contains dead leaves as a raw material.SELECTED DRAWING: Figure 1
Low Intensity focused ultrasound pulsation (LIFUP) will be administered to the amygdala while participants are in the MRI scanner. Then, 2 weeks later, entorhinal cortex LIFUP will be administered.
Methods and compositions for performing RNA interference comprising a wide variety of stabilized siRNAs suitable for use in serum-containing media and for in vivo applications, such as therapeutic applications, are provided. These siRNAs permit effective and efficient applications of RNA interference to applications such as diagnostics and therapeutics through the use of one or more modifications including orthoesters, terminal conjugates, modified linkages and 2'modified nucleotides. Uniquely modified siRNAs have been developed that reduces off-target effects incurred in gene-silencing. The modifications include phosphorylation of the first 5' terminal antisense nucleotide; 2' carbon modifications of the first and second or first, second, and third 5' terminal antisense nucleotides; and optionally 2' carbon modifications of the first and second or first, second, and third 5' terminal sense nucleotide. Control and exaequo molecules are also provided. siRNA molecules and related control, trackability and exaequo agents with specific stability modifications were developed.
Trichotillomania (TTM) is a chronic impulse control disorder that causes people to pull out their own hair. TTM typically develops in late childhood or early adolescence. It has been suggested that, like with obsessive-compulsive disorder, early identification and treatment of TTM might prevent the disorder and other co-occurring disorders in adults. The researchers in this study have developed the first treatment for TTM to target children and adolescents. Preliminary trials of this treatment, called behavior therapy (BT), indicate efficacy. This study is a larger, more rigorous examination of whether BT can successfully treat children and adolescents with TTM.

Participation in this study will be divided into two phases, each lasting 8 weeks. Follow-up visits will occur 3 and 6 months after completing treatment. In Phase 1, participants will be randomly assigned to receive either BT or supportive counseling (SC) for their TTM. Both groups of participants will complete eight weekly study visits. Those receiving BT will be encouraged to identify situations in which hair pulling is likely to occur and use behavioral techniques to resist urges to pull their hair. BT will also involve self-monitoring and homework throughout the week. Those receiving SC will discuss ways to minimize interference of hair pulling with everyday life and receive education and emotional support from a study therapist-but will not be taught specific behavioral techniques. After 8 weeks, participants will be evaluated to determine whether treatment is helping them. If participants are receiving BT and showing reduction in symptoms, they will continue to Phase 2, which involves four maintenance sessions of BT over 8 weeks. If participants receiving BT are not responding to treatment, they will be given referrals to other services. Participants receiving SC will end their participation after 8 weeks, and those not responding to treatment will be offered BT.

Study assessments will be completed at baseline, after Phase 1, after Phase 2, and at 3- and 6-month follow-ups. These assessments will include a clinical interview, questionnaires about symptoms, and family assessment measures.
PURPOSE:To carry out the purification of interferon in high efficiency, suppressing the denaturation of polypeptide and the decomposition with protease, by adding protamine to the cultured product of microorganism capable of producing physiologically active polypeptide and obtained by a recombinant DNA technique, and carrying out the extraction and purification of the objective interferon. CONSTITUTION:A microbial strain transformed by a plasmid vector containing a gene coding a physiologically active polypeptide [e.g. human immunity interferon (h-INF-gamma)-producing Escherichia coli W3110/PIN5T4N143, etc.] is cultured in a medium containing e.g. 3(wt)% polypeptone, 2% yeast extract, 2% glucose, 0.5% KH2PO4, 0.01% MgSO4.7H2O, and 20mug/ml of tetracycline, at 30 deg.C for 24hr under aeration and agitation, and the proliferated cells are separated by centrifugal separation. The cells are suspended in a tris-hydrochloric acid buffer solution of 7.5pH, added with protamine, disintegrated under ice-cooling, and centrifuged to obtain supernatant liquid. The supernatant liquid is purified e.g. by ammonium sulfate fractionation, chelate column fractionation, etc.
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention describes the novel substituted 6H-1,3,4-thiadiazine-2-amines of the general formula (I)   where   means morpholine, thiomorpholine, piperidine, pyrrolidine or hexamethyleneimine fragment, or their pharmaceutically acceptable salts. Compounds can be used as anesthetics, cardiovascular and hypometabolic agents. Invention relates to also pharmaceutical composition containing these compounds. EFFECT: valuable medicinal properties of compounds. 6 cl, 2 tbl, 7 ex
The invention discloses an orally administrative traditional Chinese medicine prescription for treating diabetes, and belongs to the field of traditional Chinese medicine. The orally administrative traditional Chinese medicine prescription for treating the diabetes is prepared from 10 to 30 grams of radix astragali, 10 to 20 grams of radix pseudostellariae, 10 to 20 grams of radix rehmanniae recen, 10 to 20 grams of medlar, 8 to 15 grams of radix glehniae, 10 to 15 grams of tuckahoe, 6 to 12 grams of dwarf lilyturf turber, 10 to 15 grams of yam, 9 to 15 grams of trichosanthes root, 8 to 12 grams of raspberry, 6 to 10 grams of Alisma orientale, 6 to 12 grams of rhizoma anemarrhenae, 9 to 15 grams of figwort, 2 to 6 grams of shizandra, and 2 to 8grams of liquorice. The prescription is decocted by water and is taken one dose every day. Fifteen days are taken as one treatment course. The traditional Chinese medicine prescription can play roles in supplementing qi and nourishing yin, and nourishing spleen and tonifying kidney. Raw materials have wide sources, are cheap and available, and also have no toxic side effect.
An implantable medical device and method are provided for comprising a sensing circuit that is configured to sense and output physiologic data indicative of a physiologic characteristic of a patient and at least one processor. A memory is coupled to the at least one processor. The memory stores program instructions and processed data. The program instructions are executable by the at least one processor to execute general operational functions within the IMD. A hybrid signal processing (HSP) circuit is coupled to the at least one processor and the sensing circuit. The HSP circuit is adapted to filter the physiologic data. The HSP circuit comprises a plurality of first order filters, a plurality of higher order filters, and a switch matrix that is configured to interconnect a combination of the first and higher order filters to form a hybrid digital filter having a select composite frequency response that utilizes no more than a select power demand.
Clascoterone cream (0.1%, 1%, or 5%) was not carcinogenic after daily topical administration in a 2-year carcinogenicity study in rats. An increased incidence of the non-neoplastic finding of atrophy of the skin and subcutis at the application site was reported in males and females treated with 1% and 5% clascoterone cream.

Clascoterone was not mutagenic in the Ames reverse mutation assay and was not clastogenic in the in vitro human lymphocyte chromosomal aberration assay. In rats, clascoterone administered via subcutaneous injection did not induce micronuclei in the bone marrow at 500 or 1000 mg/kg but a slight increase in micronuclei occurred in 2 of 5 rats at 2000 mg/kg. The response was considered equivocal. Overall, the weight of evidence indicates that clascoterone does not represent a genotoxic risk.

In a fertility and early embryonic development study in rats, clascoterone was administered subcutaneously at doses of 0.5, 2.5, or 12.5 mg/kg/day from 2 – 4 weeks before mating through mating. Clascoterone increased pre-implantation loss at 12.5 mg/kg/day (163 times the MRHD based on AUC comparison). Clascoterone had no effects on mating or fertility in rats at doses up to 12.5 mg/kg/day (163 times the MRHD based on AUC comparison). No effects were noted on development at doses up to 2.5 mg/kg/day (33 times the MRHD based on AUC comparison).
Within each cancer type, 40 patients will be enrolled (for a total of 120 patients on study): 20 patients will be enrolled with locally advanced disease ("window") and treated with durvalumab 1500 mg given by IV x 1 dose and oleclumab 3000 mg x 2 doses every 2 weeks prior to definitive therapy (e.g. surgery).
Use existing data to define surveillance strategy in use for patients in this cohort. We will use 10 randomly selected lung cancer resection patients from each accredited institution with stage I-III NSCLC (potentially curative resection) diagnosed in 2006-2007 and with 5 years of complete follow up or reported as deceased before 2012.
ISIS 681257 administered and pharmacokinetic assessments are taken. Then ISIS 681257 is administered with warfarin and additional pharmacokinetic information is obtained.